[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.87.119.171. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
March 2007

Widespread Granulomatous Dermatitis of InfancyAn Early Sign of Blau Syndrome

Author Affiliations

Author Affiliations: The Ronald O. Perelman Department of Dermatology (Drs Schaffer, Keegan, and Shin) and Departments of Pediatrics (Drs Schaffer and Shin) and Pathology (Drs Chandra and Heller), New York University School of Medicine, New York; and the Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ (Dr Shin).

Arch Dermatol. 2007;143(3):386-391. doi:10.1001/archderm.143.3.386
Abstract

Background  Pediatric sarcoidosis has traditionally been divided into 2 distinct groups: (1) school-aged children and adolescents with frequent involvement of the lungs and mediastinal lymph nodes (similar to adult sarcoidosis) and (2) infants and preschoolers with the triad of arthritis, uveitis, and a cutaneous eruption of discrete small papules, referred to as early-onset sarcoidosis. Blau syndrome, a rare autosomal dominant genodermatosis caused by mutations in the NOD2 (nucleotide-binding oligomerization domain 2) gene, has been considered as the familial form of early-onset sarcoidosis.

Observations  A 9-month-old boy developed an asymptomatic eruption of 1- to 2-mm, red-brown to pinkish tan, flat-topped papules on the face, trunk, and extremities. There was no evidence of ocular involvement or arthritis. The skin lesions were characterized histologically by noncaseating granulomas in a periadnexal distribution within the dermis. A family history of uveitis supported a diagnosis of Blau syndrome, and analysis of the NOD2 gene revealed a heterozygous gain-of-function missense mutation (Arg334Trp) that has previously been detected in Blau syndrome kindreds.

Conclusion  We draw attention to granulomatous dermatitis as an early manifestation of Blau syndrome and highlight emerging molecular evidence that this heritable autoinflammatory disorder and early-onset sarcoidosis represent a single disease entity.

Sarcoidosis, a multisystem granulomatous disease of unknown origin, has traditionally been divided into 2 distinct pediatric forms.1,2 School-aged children and adolescents with sarcoidosis have manifestations similar to those of adults, with frequent involvement of the lungs and mediastinal lymph nodes. Skin lesions are observed in approximately one third of such cases. In contrast, early-onset sarcoidosis (EOS) (also known as preschool or lichenoid sarcoidosis) typically presents with the triad of arthritis, uveitis, and a cutaneous eruption of small papules but spares the lungs and lymph nodes.15 Only 5% of pediatric cases of sarcoidosis occur in patients younger than 5 years, with an incidence rate of less than 1 per 1.5 million person-years.6 Unlike most types of sarcoidosis, the early-onset variant favors white rather than black individuals.5

Blau syndrome (BS), a rare autosomal dominant genodermatosis caused by mutations in the NOD2 (nucleotide-binding oligomerization domain 2) (also known as caspase recruitment domain family, member 15 or CARD15) gene, has considerable overlap with EOS and is thought to represent the familial form of the disease.711 In addition to synovitis, uveitis, and a generalized papular skin eruption, all characterized histologically by noncaseating granulomas, individuals with BS often develop camptodactyly (flexion contractures of the proximal interphalangeal joints) and other sequelae of chronic progressive arthritis.12,13 Of note, the latter can also occur in the setting of long-standing joint disease due to sporadic EOS.3,4,14 The age at onset, organ systems involved, and severity of BS vary substantially, even within affected families.12 The disease becomes evident at a median age of 2 years (range, 4 months to 27 years).7,1233 Skin lesions represent the first manifestation of BS in more than half of patients (51 of 93 reported cases for which the information was provided), with a median age at onset of 1 year in this subgroup.7,12,13,1627,29,30,3237 Eventually, skin, joint, and eye findings are observed in 73%, 91%, and 67% of patients with BS, respectively (a total of 174 reported cases).7,1038

We describe an infant boy who developed a generalized eruption of discrete, flat-topped papules characterized histologically by noncaseating granulomas in a periadnexal distribution within the dermis. A family history of uveitis supported a diagnosis of BS, and analysis of the NOD2 gene revealed a heterozygous gain-of-function missense mutation. We draw attention to granulomatous dermatitis as an early manifestation of BS and discuss emerging molecular evidence that this heritable autoinflammatory disorder and EOS represent a single disease entity (hereafter referred to as BS/EOS).

REPORT OF A CASE

A 12-month-old boy of Brazilian descent presented with a 3-month history of asymptomatic, discrete papules in a widespread distribution. The eruption began on the face, then spread to the trunk and extremities. He had previously been diagnosed as having atopic dermatitis but had not responded to therapy with high-potency topical corticosteroids. A 2-week course of oral prednisolone resulted in some improvement, but the condition recurred immediately on discontinuation of the prednisolone regimen.

The patient had never traveled outside the United States and was otherwise healthy, with no fevers, joint pain or swelling, eye pain, photophobia, visual changes, cough, or abdominal discomfort. An ophthalmologic examination disclosed no abnormalities. His father, paternal uncle, and paternal grandfather (Figure 1) all had a history of chronic uveitis that had begun in adolescence and required long-term oral corticosteroid therapy. The uncle also developed granulomatous dermatitis as an adult; the father and grandfather had no history of granulomatous skin lesions. There was no family history of arthritis.

Figure 1.
Pedigree of this Blau syndrome kindred. Squares indicate males; circles, females; diagonal line, deceased; and arrow, our patient.

Pedigree of this Blau syndrome kindred. Squares indicate males; circles, females; diagonal line, deceased; and arrow, our patient.

On physical examination, numerous 1- to 2-mm, red-brown to pinkish tan, flat-topped papules covered much of the face, trunk, and extremities (Figure 2). Individual lesions were closely grouped in oval clusters and linear arrays, with confluence on the face. The upper part of the chest, knees, elbows, palms, and soles were relatively spared. No oral mucosal or conjunctival lesions were evident. No joint tenderness or swelling, lymphadenopathy, or hepatosplenomegaly was found.

Figure 2.
Numerous red-brown to pinkish tan, flat-topped papules on the anterior trunk (A), back (B), and arm (C).

Numerous red-brown to pinkish tan, flat-topped papules on the anterior trunk (A), back (B), and arm (C).

The following laboratory tests produced normal results: complete blood cell count, chemistry panel, serum calcium level, hepatic function panel, erythrocyte sedimentation rate, and urinalysis. The serum angiotensin-converting enzyme level was 159 U/L (reference range, 13-100 U/L). A tuberculin skin test result was negative, chest radiograph results were normal, and ultrasonography of the wrists, elbows, and knees revealed no synovial thickening or effusions.

Histologic evaluation of a biopsy specimen from a papule on the thigh demonstrated a perifollicular, perieccrine, superficial, and deep nonnecrotizing granulomatous infiltrate composed of mononucleated and multinucleated histiocytes admixed with a few scattered neutrophils (Figure 3). Polarization failed to reveal foreign material, and acid-fast bacilli, Fite, and Grocott stains were negative for organisms.

Figure 3.
Perifollicular distribution of a nonnecrotizing granulomatous infiltrate (A) (hematoxylin-eosin, original magnification ×100) composed of mononucleated and multinucleated histiocytes admixed with a few scattered neutrophils (B) (hematoxylin-eosin, original magnification ×400).

Perifollicular distribution of a nonnecrotizing granulomatous infiltrate (A) (hematoxylin-eosin, original magnification ×100) composed of mononucleated and multinucleated histiocytes admixed with a few scattered neutrophils (B) (hematoxylin-eosin, original magnification ×400).

Together with the clinical presentation and family history, the histologic findings supported a diagnosis of BS. Genetic analysis via direct sequencing of the NOD2 gene revealed a heterozygous gain-of-function missense mutation (Arg334Trp) that has previously been detected in BS kindreds.

The patient's cutaneous eruption faded without further therapy during the next several months, but it subsequently recurred and persisted for more than 6 months. Treatment with oral azithromycin (10 mg/kg 3 times weekly) for 2 months was associated with marked improvement. The skin lesions recurred within a month of discontinuation of azithromycin therapy and faded again when it was restarted, with residual follicular atrophoderma on the trunk and extremities. At age 2 years (while receiving azithromycin), the patient was noted at a routine dermatologic follow-up visit to have nontender, boggy synovial swelling of the wrists and knees. The joint involvement was asymptomatic and had not been evident to his parents. A complete rheumatologic evaluation is under way, with plans for treatment with a tumor necrosis factor inhibitor.

COMMENT

For the past 2 decades, controversy has existed regarding nomenclature for and classification of EOS and BS.8,9,39,40 In 1986, Miller8 recognized that the 2 conditions are clinically indistinguishable (apart from the presence or absence of a family history) and proposed the unifying term juvenile systemic granulomatosis. Blau9 later supported the concept that EOS and the “autosomal dominant granulomatous disease of childhood” that he first reported in 1985 actually represent the same disorder.

The recent identification of the same heterozygous NOD2 mutations in individuals with sporadic EOS and members of BS families confirmed that these diseases are identical on genetic and clinical levels.2932 Kanazawa et al31 found that 9 of 10 Japanese patients with EOS had a pathogenic, presumably de novo, NOD2 mutation, whereas Wang et al11 detected NOD2 mutations in 5 of 10 families with a clinical diagnosis of BS. In contrast, several studies have failed to identify NOD2 mutations in patients with classic sarcoidosis of adolescent or adult onset (N = 357), including those with a family history.4143 Molecular evidence thus supports the existence of EOS/BS as a distinct disease entity. Since the NOD2 mutations that characterize BS appear to have nearly 100% penetrance (ie, all individuals with these mutations express the disease phenotype) and the disorder does not affect reproductive potential,10,44,45 the de novo mutations that underlie EOS are likely to generate new Blau pedigrees.19 For example, a young girl initially reported to have sporadic EOS characterized by a papular rash, uveitis, arthritis, and large-vessel vasculitis later gave birth to a child who developed similar skin lesions and arthritis, changing the diagnosis to BS.32,45

Of note, a completely different set of NOD2 variants has been associated with Crohn disease, increasing the likelihood of this complex polygenic condition 20- to 40-fold in homozygotes or compound heterozygotes. This confers a lifetime risk of approximately 10%, reflecting the need for an environmental trigger to develop clinical Crohn disease.46 The same polymorphisms lead to an increased risk of severe, acute graft-vs-host disease after hematopoietic stem cell transplantation.

The NOD2 protein is a member of the NOD family of cytosolic pattern-recognition molecules. Like their transmembrane counterparts, the toll-like receptors, NODs recognize highly conserved components of microorganisms and subsequently stimulate the innate immune response.46 NOD2, which is expressed by monocytes and intestinal epithelial cells (particularly within ileal crypts, a primary site of inflammation in Crohn disease), specifically recognizes the muramyl dipeptide component of bacterial cell wall peptidoglycan.47,48 This interaction leads to NOD2 oligomerization and activation of the nuclear factor (NF)–κB inflammatory cascade and regulation of apoptosis.4648

NOD2 mutations reported in patients with EOS/BS (with Arg334Gln/Trp accounting for 28 of 37 cases or families) affect the nucleotide-binding domain of the protein and lead to increased activation of NF-κB that is independent of muramyl dipeptide stimulation (ie, constitutive gain of function).3537,49 In contrast, NOD2 polymorphisms that are associated with susceptibility to Crohn disease are located in leucine-rich repeat regions of the protein product and impair responsiveness to muramyl dipeptide (ie, loss of function).49,50 Paradoxically, despite a decrease in NOD2-induced NF-κB signaling, Crohn disease is characterized by increased levels of NF-κB target gene products such as IL-12 (interleukin 12) and tumor necrosis factor α and, as in EOS/BS, granulomatous inflammation.50 Possible explanations include reduced bacterial recognition and clearance (eg, via decreased production of antimicrobial peptides such as β-defensin-2) in the gastrointestinal tract leading to impaired epithelial defense and secondary inflammation, loss of NOD2-mediated inhibition of toll-like receptor 2–induced NF-κB activation, and a variable balance of proinflammatory and anti-inflammatory consequences of defective NOD2 signaling in different contexts (eg, mucosal epithelia with commensal bacteria vs monocytes in aseptic sites).46,48,50

The asymptomatic papular eruption that characterizes EOS/BS is rarely observed in older children and adults with sarcoidosis.51 Discrete, pinhead-sized papules typically first appear on the face and extremities and subsequently spread to the trunk. The yellowish to red-brown, slightly scaly, flat-topped papules have been likened to “tapioca grains.”52 They tend to be arranged in clusters or linear arrays but can become confluent, and a perifollicular distribution may be evident.3,4,14,24,27,32,53,54 Intermittent episodes of widespread skin disease with spontaneous resolution usually occur during a period of years (in contrast to the more persistent skin lesions of sarcoidosis). Poikiloderma has been observed in older patients,13,27 and pitted scars due to follicular atrophoderma are sometimes apparent at sites of previous inflammatory papules.2,3,27,5457 Ichthyosiform skin changes characterized histologically by a hyperkeratotic epidermis with underlying dermal granulomas have also been described in EOS/BS.2,4,27,30,34,55

Histologically, the naked noncaseating granulomas of EOS/BS involve primarily the upper dermis and often have a perifollicular distribution.24,54 This histologic pattern is identical to that of lichen scrofulosorum, a tuberculid that is usually seen in children with tuberculosis that involves the lymph nodes and bones. Lichen scrofulosorum also has a clinical appearance similar to that of EOS/BS, although it favors the trunk rather than the extremities and face.58 Tuberculin skin testing should therefore be considered in patients with features of EOS/BS.

The symmetric polyarthritis of EOS/BS typically presents with nontender, boggy joint swelling due to synovial thickening and effusion.25 The wrists, knees, and ankles are most frequently affected.3 Massive swelling of the tendon sheaths and synovia accompanied by a relatively normal range of motion, minimal pain, and a lack of x-ray film evidence of erosive joint changes until later in the disease process favor a diagnosis of EOS/BS instead of juvenile rheumatoid arthritis.13,59

Anterior or panuveitis is the most common ocular manifestation of EOS/BS and may present with eye pain, photophobia, and blurred vision.14,28,38 Granulomatous inflammation can also involve the conjunctiva, lacrimal glands, retina, and optic nerve, and ocular complications include cataracts and glaucoma.28 Because early ocular disease is often asymptomatic and its onset can be delayed, slitlamp examination should be performed on a regular basis.60 Permanent sequelae of chronic inflammation in the eyes and/or joints develop in more than 80% of patients with EOS/BS,14,38 and anticipation (increased severity in successive generations) has been described in familial cases.17,21

The clinical manifestations of EOS/BS can extend beyond the classic triad. Additional systemic features have included cranial neuropathies11,17; granulomatous large-vessel vasculitis that involves the carotid, renal, and cerebral arteries11,1416,19,24,61,62; and granulomatous inflammation of the liver, kidneys, lung, heart, and epididymis (typically occurring in later stages of the disease).14,16,23,26,30,55,63 Some patients have also presented with recurrent fevers, which are infrequently observed in typical EOS/BS.1416,19,23,29,64 The inclusion of disorders initially reported as “familial granulomatous synovitis, uveitis, and cranial neuropathies”17 and “familial granulomatous arteritis with polyarthritis”16 within the clinical spectrum of BS is supported by the documentation of NOD2 mutations (including Arg334Gln/Trp) in these subsets of patients.10,11,23,32 It is likely that additional modifying genes have a role in the development of EOS/BS with prominent involvement of large blood vessels and internal organs.

The cutaneous eruption of EOS/BS may respond to potent topical corticosteroids but tends to recur once use of the corticosteroids is discontinued.54,59 In patients with uveitis, progressive joint disease, visceral involvement, or skin lesions that are extensive and/or symptomatic, therapy is often initiated with systemic corticosteroids. Because the granulomatous inflammation is prone to relapse on medication withdrawal, steroid-sparing agents such as tumor necrosis factor inhibitors (eg, infliximab), methotrexate, cyclosporine, and other immunosuppressive medications may be required.4,14,32,35,36,38 Immunomodulatory agents that target IL-1 (a proinflammatory cytokine that is up-regulated by NF-κB) may also have therapeutic potential in EOS/BS.35 In our patient, azithromycin (which has anti-inflammatory properties that include inhibition of tumor necrosis factor α production) was beneficial for the skin lesions but not the arthritis.

As exemplified by our patient, EOS/BS tends to first become evident in the skin.1,2,12 Recognizing the characteristic cutaneous eruption and confirming the presence of granulomas via skin biopsy are critical steps to establishing the diagnosis. Dermatologists then have an important opportunity to institute monitoring that will facilitate the early detection and treatment of ocular, rheumatologic, and other systemic manifestations. In addition, genetic counseling and prenatal diagnosis based on analysis of the NOD2 gene can be offered. We disagree with the recent suggestion by Becker and Rose45 to rename EOS/BS pediatric granulomatous arthritis because this term does not encompass the full disease spectrum and might deter physicians from considering the diagnosis in early or “incomplete” cases such as those described in this report. Arthritis is absent in half of patients at the time of initial presentation, and it never develops in approximately 10% of affected individuals.7,1038 Increased awareness of EOS/BS will allow identification and genetic testing of additional affected individuals and families, helping to expand the allelic series of underlying NOD2 mutations and further define genotype-phenotype correlations.

Back to top
Article Information

Correspondence: Julie V. Schaffer, MD, The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, 560 First Ave, Room H-100, New York, NY 10016 (schafj04@med.nyu.edu).

Financial Disclosure: None reported.

Accepted for Publication: August 8, 2006.

Author Contributions: Dr Schaffer had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Schaffer. Acquisition of data: Schaffer, Chandra, Keegan, and Heller. Analysis and interpretation of data: Schaffer, Heller, and Shin. Drafting of the manuscript: Schaffer. Critical revision of the manuscript for important intellectual content: Schaffer, Chandra, Keegan, Heller, and Shin. Administrative, technical, and material support: Schaffer, Chandra, and Heller. Study supervision: Schaffer, Heller, and Shin.

References
1.
Hetherington  S Sarcoidosis in young children. AJDC 1982;13613- 15
PubMed
2.
Rosenberg  AMYee  EHMacKenzie  JW Arthritis in childhood sarcoidosis. J Rheumatol 1983;10987- 990
PubMed
3.
North  AF  JrFink  CWGibson  WM  et al.  Sarcoid arthritis in children. Am J Med 1970;48449- 455
PubMedArticle
4.
Mallory  SBPaller  ASGinsburg  BCMcCrossin  IDAbernathy  R Sarcoidosis in children: differentiation from juvenile rheumatoid arthritis. Pediatr Dermatol 1987;4313- 319
PubMedArticle
5.
Sahn  EEHampton  MTGaren  PDWarrick  JSmith  DSilver  RM Preschool sarcoidosis masquerading as juvenile rheumatoid arthritis: two case reports and a review of the literature. Pediatr Dermatol 1990;7208- 213
PubMedArticle
6.
Hoffmann  ALMilman  NByg  KE Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr 2004;9330- 36
PubMedArticle
7.
Blau  EB Familial granulomatous arthritis, iritis, and rash. J Pediatr 1985;107689- 693
PubMedArticle
8.
Miller  JJ  III Early-onset sarcoidosis and “familial granulomatous arthritis (arteritis)”: the same disease. J Pediatr 1986;109387- 388
PubMedArticle
9.
Blau  EB Autosomal dominant granulomatous disease of childhood: the naming of things. J Pediatr 1998;133322- 323
PubMedArticle
10.
Miceli-Richard  CLesage  SRybojad  M  et al.  CARD15 mutations in Blau syndrome. Nat Genet 2001;2919- 20
PubMedArticle
11.
Wang  XKuivaniemi  HBonavita  G  et al.  CARD15 mutations in familial granulomatosis syndromes: a study of the original Blau syndrome kindred and other families with large-vessel arteritis and cranial neuropathy. Arthritis Rheum 2002;463041- 3045
PubMedArticle
12.
Manouvrier-Hanu  SPeuch  BPiette  F  et al.  Blau syndrome of granulomatous arthritis, iritis, and skin rash: a new family and review of the literature. Am J Med Genet 1998;76217- 221
PubMedArticle
13.
Alonso  DElgart  GWSchachner  LA Blau syndrome: a new kindred. J Am Acad Dermatol 2003;49299- 302
PubMedArticle
14.
Häfner  RVogel  P Sarcoidosis of early onset: a challenge for the pediatric rheumatologist. Clin Exp Rheumatol 1993;11685- 691
PubMed
15.
Malleson  PSchaller  JGDega  FCassidy  SBPagon  RA Familial arthritis and camptodactyly. Arthritis Rheum 1981;241199- 1204
PubMedArticle
16.
Rotenstein  DGibbas  DMajmudar  BChastain  EA Familial granulomatous arteritis with polyarthritis of juvenile onset. N Engl J Med 1982;30686- 90
PubMedArticle
17.
Jabs  DAHouk  JLBias  WBArnett  FC Familial granulomatous synovitis, uveitis, and cranial neuropathies. Am J Med 1985;78801- 804
PubMedArticle
18.
Pastores  GMMichels  VVStickler  GBSu  WPDNelson  AMBovenmyer  DA Autosomal dominant granulomatous arthritis, uveitis, skin rash, and synovial cysts. J Pediatr 1990;117403- 408
PubMedArticle
19.
Rose  CDEichenfield  AHGoldsmith  DPAthreya  BH Early onset sarcoidosis with aortitis – “juvenile systemic granulomatosis”? J Rheumatol 1990;17102- 106
PubMed
20.
de Chadarévian  JPRaphael  SAMurphy  GF Histologic, ultrastructural, and immunocytochemical features of the granulomas seen in a child with the syndrome of familial granulomatous arthritis, uveitis, and rash. Arch Pathol Lab Med 1993;1171050- 1052
PubMed
21.
Raphael  SABlau  EBZhang  WHHsu  SU Analysis of a large kindred with Blau syndrome for HLA, autoimmunity, and sarcoidosis. AJDC 1993;147842- 848
PubMed
22.
Moraillon  IHayem  FBourrillon  AMorel  PRybojad  M Syndrome de Blau ou forme familiale de sarcoïdose à début infantile. Ann Dermatol Venereol 1996;12329- 30
PubMed
23.
Saini  SKRose  CD Liver involvement in familial granulomatous arthritis (Blau syndrome). J Rheumatol 1996;23396- 399
PubMed
24.
Scerri  LCook  LJJenkins  EAThomas  AL Familial juvenile systemic granulomatosis (Blau's syndrome). Clin Exp Dermatol 1996;21445- 448
PubMedArticle
25.
Tromp  GKuivaniemi  HRaphael  S  et al.  Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16. Am J Hum Genet 1996;591097- 1107
PubMed
26.
Ting  SSZiegler  JFischer  E Familial granulomatous arthritis (Blau syndrome) with granulomatous renal lesions. J Pediatr 1998;133450- 452
PubMedArticle
27.
Ewida  ASRaphael  SAAbbasi  JAGeslani  GPBagasra  O Evaluation of Th-1 and Th-2 immune responses in the skin lesions of patients with Blau syndrome. Appl Immunohistochem Mol Morphol 2002;10171- 177
PubMedArticle
28.
Kurokawa  TKikuchi  TOhta  KImai  HYoshimura  N Ocular manifestations in Blau syndrome associated with a CARD15/Nod2 mutation. Ophthalmology 2003;1102040- 2044
PubMedArticle
29.
Kanazawa  NMatsushima  SKambe  NTachibana  TNagai  SMiyachi  Y Presence of a sporadic case of systemic granulomatosis syndrome with a CARD15 mutation. J Invest Dermatol 2004;122851- 852
PubMedArticle
30.
Priori  RBombardieri  MSpinelli  FR  et al.  Sporadic Blau syndrome with a double CARD15 mutation. Sarcoidosis Vasc Diffuse Lung Dis 2004;21228- 231
PubMed
31.
Kanazawa  NOkafuji  IKambe  N  et al.  Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-κB activation: common genetic etiology with Blau syndrome. Blood 2005;1051195- 1197
PubMedArticle
32.
Rosé  CDDoyle  TMMcIlvain-Simpson  G  et al.  Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol 2005;32373- 375
PubMed
33.
van Duist  MMAlbrecht  MPoswiadek  M  et al.  A new CARD15 mutation in Blau syndrome. Eur J Hum Genet 2005;13742- 747
PubMedArticle
34.
Masel  GHalbert  A Blau syndrome presenting with ichthyosis. Australas J Dermatol 2005;4629- 32
PubMedArticle
35.
Rose  CDWouters  CHMeiorin  S  et al.  Pediatric granulomatous arthritis: an international registry. Arthritis Rheum 2006;543337- 3344
PubMedArticle
36.
Milman  NAndersen  CBHansen  A  et al.  Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. APMIS 2006;114912- 919
PubMedArticle
37.
Snyers  BDahan  K Blau syndrome associated with a CARD15/NOD2 mutation. Am J Ophthalmol 2006;1421089- 1092
PubMedArticle
38.
Latkany  PAJabs  DASmith  JR  et al.  Multifocal choroiditis in patients with familial juvenile systemic granulomatosis. Am J Ophthalmol 2002;134897- 904
PubMedArticle
39.
Mallory  SBPaller  A Blau syndrome versus sarcoidosis [letter; comment]. J Pediatr 1991;119503
PubMedArticle
40.
James  G Blau's syndrome and sarcoidosis [letter; comment]. Lancet 1999;3541035
PubMedArticle
41.
Martin  TMDoyle  TMSmith  JRDinulescu  DRust  KRosenbaum  JT Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15). Am J Ophthalmol 2003;136933- 935
PubMedArticle
42.
Schürmann  MValentonyte  RHampe  JMüller-Quernheim  JSchwinger  ESchreiber  S CARD15 gene mutations in sarcoidosis. Eur Respir J 2003;22748- 754
PubMedArticle
43.
Ho  LPMcMichael  AJDavies  JOGaber  KHugot  JPMerlin  F CARD 15 gene mutations in sarcoidosis. Thorax 2005;60354- 355
PubMedArticle
44.
Becker  MLRose  CMartin  TM  et al.  CARD15 mutations in Blau syndrome families: experience between two centers [abstract]. Arthritis Rheum 2004;48S362
45.
Becker  MLRose  CD Blau syndrome and related genetic disorders causing childhood arthritis. Curr Rheumatol Rep 2005;7427- 433
PubMedArticle
46.
Inohara  HChamaillard  MMcDonald  CNuñez  G NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005;74355- 383
PubMedArticle
47.
Ogura  YInohara  NBenito  AChen  FFYamaoka  SNunez  G Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J Biol Chem 2001;2764812- 4818
PubMedArticle
48.
Eckmann  LKarin  M NOD2 and Crohn's disease: loss or gain of function? Immunity 2005;22661- 667
PubMedArticle
49.
Chamaillard  MPhilpott  DGirardin  SE  et al.  Gene-environment interaction moduled by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A 2003;1003455- 3460
PubMedArticle
50.
Kelsall  B Getting to the guts of NOD2. Nat Med 2005;11383- 384
PubMedArticle
51.
Fujii  KOkamoto  HOnuki  MHorio  T Recurrent follicular and lichenoid papules of sarcoidosis. Eur J Dermatol 2000;10303- 305
PubMed
52.
Tilly  JJDrolet  BAEsterly  NB Lichenoid eruptions in children. J Am Acad Dermatol 2004;51606- 624
PubMedArticle
53.
Gross  KRMalleson  PNCulham  GLiernman  DSMcCormick  AQPetty  RE Vasculopathy with renal artery stenosis in a child with sarcoidosis. J Pediatr 1986;108724- 726
PubMedArticle
54.
Seo  SKYeum  JSSuh  JCNa  GY Lichenoid sarcoidosis in a 3-year-old girl. Pediatr Dermatol 2001;18384- 387
PubMedArticle
55.
Gluck  JMiller  JJSummerlin  WT Sarcoidosis in a young child. J Pediatr 1972;81354- 357
PubMedArticle
56.
Rasmussen  JE Sarcoidosis in young children. J Am Acad Dermatol 1981;5566- 570
PubMedArticle
57.
Clark  SK Sarcoidosis in children. Pediatr Dermatol 1987;4291- 299
PubMedArticle
58.
Sehgal  VN Lichen scrofulosorum: current status. Int J Dermatol 2005;44521- 523
PubMedArticle
59.
Fetil  EÖzkan  ŞIlknur  TKavukçu  SKuşku  ELebe  B Sarcoidosis in a preschooler with only skin and joint involvement. Pediatr Dermatol 2003;20416- 418
PubMedArticle
60.
Osborne  GEMallon  EMayou  SC Juvenile sarcoidosis after BCG vaccination. J Am Acad Dermatol 2003;48S99- S102
PubMedArticle
61.
Gedalia  AShetty  AKWard  KCorrea  HVenters  CLLoe  WA Abdominal aortic aneurysm associated with childhood sarcoidosis. J Rheumatol 1996;23757- 759
PubMed
62.
Shetty  AKGedalia  A Pediatric sarcoidosis. J Am Acad Dermatol 2003;48150- 151
PubMedArticle
63.
Bautista  A Childhood sarcoidosis involving joints and kidneys. AJDC 1970;119259- 263
PubMed
64.
Fink  CWCimaz  R Early onset sarcoidosis: not a benign disease. J Rheumatol 1997;24174- 177
PubMed
×